Benefits of ASPET’s Partnership with Elsevier
The start of 2025 marks an important milestone for ASPET and its highly respected and influential journals program. Beginning January 1, all of ASPET’s wholly owned journals (The Journal of Pharmacology and Experimental Therapeutics, Pharmacological Reviews, Drug Metabolism and Disposition, and Molecular Pharmacology) are now published on Elsevier’s platform. This change comes for ASPET after approximately 30 years of self-publishing, so rest assured that this change was not made lightly.
This decision was made to take advantage of a number of benefits for the ASPET community. For authors, this partnership provides financial flexibility so that authors will no longer be charged submission fees or page charges to publish in ASPET journals. Additionally, for those choosing to publish via open access, ASPET members will receive a 25% discount on open access fees for all of its journals. Speaking of Open Access, the partnership with Elsevier also enables ASPET to launch a new Gold Open Access journal, ASPET Discovery.
Along with removing and reducing financial barriers, partnering with Elsevier will dramatically improve the reachability and accessibility of papers. One reason for this increased reach is ASPET journal content will now be included in ScienceDirect, Elsevier’s premier platform of peer-reviewed scholarly literature that’s used by 95% of research with more than 120 million visitors each month. In addition, ASPET will benefit from the impressive marketing capabilities of Elsevier, as our journals will be promoted to the hundreds of thousands of pharmacology researchers in the Elsevier network.
Along with improving the experience for our authors, the ASPET editors and peer reviewers will also benefit from our new partnership with Elsevier. By working with the largest publisher in the world, ASPET staff and editors will have access to new analytical, bibliometric and plagiarism detection software tools to assist in the critical peer review process. It’s important to note that ASPET editors, journal boards and staff will continue to manage the journals with full editorial control.
As I shared in April 2024 when we first announced this partnership with our membership, we believe publishing with Elsevier has the potential to improve an already excellent author experience, provide more support and new tools to our reviewers and editors, and further expand the reach of our influential journals. We hope all members of the pharmacology community will experience the benefits of this partnership and consider publishing your science in one of ASPET’s journals.
Dave Jackson, MBA, CAE
Executive Officer, ASPET
